Evidence review and clinical guidance for the use of ziprasidone in Canada.

Abstract

While indicated for schizophrenia and acute mania, ziprasidone's evidence base and use in clinical practice extends beyond these regulatory approvals. We, an invited panel of experts led by a working group of 3, critically examined the evidence and our collective experience regarding the effectiveness, tolerability and safety of ziprasidone across its clinical uses. There was no opportunity for manufacturer input into the content of the review. As anticipated, ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data. Beyond these uses, the available data were either unimpressive or were lacking. An attractive characteristic is its neutral effect on weight thereby providing patients with a non-obesogenic long-term treatment option. Key challenges in practice include the need for dosing on a full stomach and managing its early onset adverse effect of restlessness. Addressing these issues are critical to its long-term success.

• Authors: David M Gardner, Andrea L Murphy, Stan Kutcher, Serge Beaulieu, Carlo Carandang, Alain Labelle, Pierre Lalonde, Ashok Malla, Heather Milliken, Claire O'Donovan, Ayal Schaffer, Jorge Soni, Valerie H Taylor, Richard Williams
• Journal: Annals of general psychiatry (Ann Gen Psychiatry) Vol. 12 Issue 1 Pg. 1 (Jan 24 2013) ISSN: 1744-859X [Print] England
• PMID: 23347694 (Publication Type: Journal Article)